Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia A von Stackelberg, F Locatelli, G Zugmaier, R Handgretinger, TM Trippett, ... Journal of Clinical Oncology 34 (36), 4381-4389, 2016 | 575 | 2016 |
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 M Brüggemann, A Schrauder, T Raff, H Pfeifer, M Dworzak, OG Ottmann, ... Leukemia 24 (3), 521-535, 2010 | 447 | 2010 |
Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM … P Bader, H Kreyenberg, GHR Henze, C Eckert, M Reising, A Willasch, ... Journal of Clinical Oncology 27 (3), 377-384, 2009 | 426 | 2009 |
Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster … HG Einsiedel, A von Stackelberg, R Hartmann, R Fengler, M Schrappe, ... Journal of clinical oncology 23 (31), 7942-7950, 2005 | 382 | 2005 |
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy … G Tallen, R Ratei, G Mann, G Kaspers, F Niggli, A Karachunsky, W Ebell, ... Journal of clinical oncology 28 (14), 2339-2347, 2010 | 375 | 2010 |
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation … P Bader, H Kreyenberg, W Hoelle, G Dueckers, R Handgretinger, P Lang, ... Journal of clinical oncology 22 (9), 1696-1705, 2004 | 319 | 2004 |
Next-generation personalised medicine for high-risk paediatric cancer patients–The INFORM pilot study BC Worst, CM van Tilburg, GP Balasubramanian, P Fiesel, R Witt, ... European journal of cancer 65, 91-101, 2016 | 310 | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 A Möricke, M Zimmermann, MG Valsecchi, M Stanulla, A Biondi, G Mann, ... Blood, The Journal of the American Society of Hematology 127 (17), 2101-2112, 2016 | 260 | 2016 |
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition J Irving, E Matheson, L Minto, H Blair, M Case, C Halsey, I Swidenbank, ... Blood, The Journal of the American Society of Hematology 124 (23), 3420-3430, 2014 | 255 | 2014 |
Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors … C Peters, M Schrappe, A von Stackelberg, A Schrauder, P Bader, W Ebell, ... Journal of clinical oncology: official journal of the American Society of …, 2015 | 252 | 2015 |
Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia J Hof, S Krentz, C Van Schewick, G Körner, S Shalapour, P Rhein, ... Journal of clinical oncology 29 (23), 3185-3193, 2011 | 243 | 2011 |
Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial F Locatelli, G Zugmaier, C Rizzari, JD Morris, B Gruhn, T Klingebiel, ... Jama 325 (9), 843-854, 2021 | 217 | 2021 |
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia V Frismantas, MP Dobay, A Rinaldi, J Tchinda, SH Dunn, J Kunz, ... Blood, The Journal of the American Society of Hematology 129 (11), e26-e37, 2017 | 215 | 2017 |
Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study C Peters, JH Dalle, F Locatelli, U Poetschger, P Sedlacek, J Buechner, ... Journal of Clinical Oncology 39 (4), 295-307, 2021 | 206 | 2021 |
Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia … C Eckert, G Henze, K Seeger, N Hagedorn, G Mann, R Panzer-Grümayer, ... Journal of clinical oncology 31 (21), 2736-2742, 2013 | 204 | 2013 |
Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group B Burkhardt, A Reiter, E Landmann, P Lang, L Lassay, R Dickerhoff, ... Journal of clinical oncology 27 (20), 3363-3369, 2009 | 201 | 2009 |
Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis A Borgmann, A von Stackelberg, R Hartmann, W Ebell, T Klingebiel, ... Blood, The Journal of the American Society of Hematology 101 (10), 3835-3839, 2003 | 197 | 2003 |
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia R Handgretinger, G Zugmaier, G Henze, H Kreyenberg, P Lang, ... Leukemia 25 (1), 181-184, 2011 | 175 | 2011 |
Negative feedback–defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL B Li, H Li, Y Bai, R Kirschner-Schwabe, JJ Yang, Y Chen, G Lu, ... Nature medicine 21 (6), 563-571, 2015 | 172 | 2015 |
Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending … P Bader, H Kreyenberg, A von Stackelberg, C Eckert, ... Journal of Clinical Oncology 33 (11), 1275-1284, 2015 | 145 | 2015 |